Home » Archive

Marketwire, News, Syndication »

Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual Property

Posted by Mary Canady June 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jun 7, 2012) – Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPh…

More...

Marketwire, News, Syndication »

Bio-Matrix’ Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in Anticipation of Beginning Clinical Development Stem Cell Studies

Posted by Mary Canady June 6th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jun 6, 2012) –

World renowned experts to accelerate development of stem cell therapeutics

Regen anticipates new relationship with Clinartis to fast track clinical studies

More...

Marketwire, News, Syndication »

Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection With Proposed Merger

Posted by Mary Canady June 5th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jun 5, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) (“Ardea”), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced the expiration of …

More...

Drug Discovery, Headline »

SDBN June 25th Event With Lilly: Open Innovation Drug Discovery

Posted by Mary Canady June 4th, 2012 .
No Comments

San Diego biotech has grown thanks to a collaborative spirit which is sometimes manifested in the acquisition and joining of companies towards a common goal. Lilly’s presence here is indicative of this type of growth, beginning with their acquisition of SGX Pharmaceuticals and Applied Molecular Evolution, and they’ve continued to move forward and contribute to the region.

The SDBN is dedicated to helping the local life science community understand and leverage the fantastic opportunities available through networking and sharing resources. Lilly is a leader in this area and formed the Open …

More...

Marketwire, News, Syndication »

Medistem Achieves Important ERC Stem Cell Clinical Trial Milestone

Posted by Mary Canady June 4th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jun 4, 2012) – Medistem Inc. (PINKSHEETS: MEDS) announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DE…

More...

Marketwire, News, Syndication »

Quidel to Present at Upcoming Conferences

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today that it will present at the following upcoming conferences:

More...

Marketwire, News, Syndication »

Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion d…

More...

Marketwire, News, Syndication »

La Jolla Pharmaceutical Announces Issuance of U.S. Patent Covering Modified Pectin Compositions

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) (the “Company” and “La Jolla”) announced today that the United States Patent and Trademark Office (USPTO) has issued patent number 8,187,642…

More...

Marketwire, News, Syndication »

NuVasive to Participate in Investor Events in June 2012

Posted by Mary Canady May 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 30, 2012) – NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company will participate in seve…

More...

Marketwire, News, Syndication »

Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate

Posted by Mary Canady May 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 30, 2012) – Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion …

More...